We’re thrilled to announce that Moroxite AB has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...

The Board of Directors of Moroxite AB has appointed Fredrik Lindberg as the new CEO, and he will start May 5, 2025.  Fredrik Lindberg MD,...

Moroxite AB has successfully raised SEK 22 million— backed by current owners and a small number of selected new investors.   This funding...

Moroxite has successfully cleared Stage 1 of the EIC Accelerator programme for our innovative product, Xerafuse™. This bone mineral...

TERM group at LU presented their work at the recently held Orthopedic Research Society's Annual Meeting . Poster:  A Calcium...

Background On-site delivery of bioactive agents facilitates enhancing the effectiveness of spinal fusion. However, the FDA-approved...

Present key target in her role at Moroxite F is regulatory approval in US

Dr. Markevičiūtė has shown that CaS/HA augmentation combined with systemic bisphosphonate could be superior to present techniques

Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been FDA-approved for lumbar fusion, but supraphysiologic initial burst...

Fracture fixation in an ageing population is challenging and fixation failure increases mortality and societal costs. We report a novel...

A clinical feasibility study, conducted in collaboration with researchers from Sweden, Lithuania, Germany, and China, have yielded...

It is reassuring and gratifying for all of us at Moroxite F to have secured the funds to be able to continue working with strong progress

Moroxite F team comprising of CTO Deepak Raina and doctoral student Jintian Huang accompanied by Prof. Stefan Zwingenberger and his team...

Assistant Professor Erdem Aras Sezgin at Aksaray University of Medicine, Department of Orthopedics and Traumatology, Turkey has on...

Despite the glimmer of hope provided by the discovery and commercialization of bone morphogenetic protein-2 (BMP-2) as a bone graft...

We are delighted to introduce two talented professionals who have recently joined our team

Our research group has collaborated with Prof. Ding to test the Fracture Anchorage and Regeneration concept in a pre-clinical setting...

TERM group at LU presented their work a the recently held EORS and International Combined Orthopedic Research Society joint meeting....

Hydroxyapatite (HA) has been widely used as a bone substitute and more recently as a carrier for local delivery of bone targeted drugs....

Cement augmentation of pedicle screws is one of the most promising approaches to enhance the anchoring of screws in the osteoporotic...